A number of heavyweight varieties have been approved for listing, involving Gilead, AstraZeneta, Lilly...

Within a week (September 18 to September 27), a number of heavyweight varieties were listed, involving international pharmaceutical companies such as Gilead, AstraZenew and Lilly, as well as domestic pharmaceutical companies such as Rongchang Bio.
Gilead and partner Galapagos NV recently jointly announced that its oral JAK1 inhibitor Jyseleca has been approved in the European Union.
the drug is an oral selective JAK1 inhibitor used to treat adult patients with moderate to severe rheumatoid arthritis (RA) who have inadequate or insatiable response to one or more disease-modified rheumatoid drugs (DMARD).
drug use, Jyseleca can be used as a monotherapy or in combination with methotrexate (MTX).
same day, Gilead and Aedes aurelis jointly announced that Japan's Ministry of Health, Labour and Industry had approved Jyseleca (200mg and 100mg tablets) for the treatment of RA patients who do not respond well to conventional therapies, including the prevention of structural joint injuries.
Under a cooperation agreement reached in December 2019, Gilead Japan holds jyseleca's sales license in Japan, and Aso will be responsible for dissecting the drug in Japan for the treatment of RA and other potential future adaptations, including ulcerative colitis, Crohn's disease, psoriasis arthritis, etc.
AstraZeneca/ First Three AstraZeneca / 13th Announced on the 26th that its jointly developed HER2 targeted antibody consonant drug (ADC) Enhertu extended adaptive disease has been approved by Japan's Ministry of Health, Labour, for the treatment of HER2 positive can not be removed in patients with advanced or relapsed stomach cancer.
patients had been treated with chemotherapy, but the disease continued to progress.
is understood to be Enhertu's first global approval to treat HER2-positive stomach cancer, which will be a boon for such cancer patients.
Lilly and partner Incyte recently announced that the European Medicines Agency (EMA) Human Medicines Products Committee (CHMP) has recommended approval of oral JAK inhibitor Olumiant for the treatment of moderate to severe endexual dermatitis (AD) adult patients suitable for systemic treatment.
approved, Olumiant would be the first JAK inhibitor to treat AD.
it is understood that adrenal dermatitis (AD) is a serious chronic inflammatory skin disease, mainly manifested in severe itching, obvious eczema-like changes and dry skin.
often from infants and young children, some patients continue for life, seriously affecting the quality of life of patients.
BMS recently, BMS and Bluebird Bio jointly announced that the FDA has accepted its BCMA CAR-T cell immunotherapy treatment for recurrence/recurring multiple myeloma market application, and granted priority review qualification.
, multiple myeloma is the second most common hematological malignancy after non-Hodgkin's lymphoma.
in recent years, the demand for new drugs in this area remains urgent.
BCMA, a transmeral glycoprotein, is a popular immunotherapy target for MM and other hematroviral tumors and has become a popular target for anti-cancer therapy after CD19.
Rongchang Bio recently, Rongchang Bio announced that its own research and development of ADC drugs by the FDA breakthrough therapy identified as HER2 expression (IHC 2 plus or IHC 3 plus) local late stage or metastatic urethra cancer patients second-line treatment.
months ago, the new drug was approved by the FDA as Fast Track.
that there are currently no treatment of HER2-positive urethra skin cancer drugs have been approved for the market.
RC48 study showed that among the 43 subjects treated with RC48-ADC for second- and multi-line urethra skin cancer, the confirmed objective remission rate (cORR) was as high as 51.2% and the disease control rate (DCR) was as high as 90.7%.
can be said to have achieved a major breakthrough, filling the huge medical needs.